Proportional hazards and recursive partitioning and amalgamation analyses of the southwest oncology group node-positive adjuvant CMFVP breast cancer data base: a pilot study

1992 ◽  
Vol 22 (3) ◽  
pp. 273-284 ◽  
Author(s):  
Kathy S. Albain ◽  
Stephanie Green ◽  
Michael LeBlanc ◽  
Saul Rivkin ◽  
Janet O'Sullivan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pilot Study ◽  
Data Base ◽  
Proportional Hazards ◽  
Recursive Partitioning ◽  
Breast Cancer Data ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Cancer Data ◽  
Node Positive

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.

1994 ◽  
Vol 12 (10) ◽  
pp. 2078-2085 ◽  
Author(s):  
S E Rivkin ◽  
S Green ◽  
B Metch ◽  
A B Cruz ◽  
M D Abeloff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Postmenopausal Women ◽  
Eastern Cooperative Oncology Group ◽  
Operable Breast Cancer ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Node Positive ◽  
Er Positive ◽  
Positive Breast Cancer

PURPOSE To compare chemohormonal therapy, chemotherapy alone, and hormonal therapy alone in postmenopausal patients with estrogen receptor (ER)-positive operable breast cancer and positive axillary nodes with respect to survival and disease-free survival (DFS). PATIENTS AND METHODS Eight hundred ninety-two postmenopausal women with ER-positive, node-positive breast cancer were enrolled by the Southwest Oncology Group (SWOG) from July 1979 to March 1989 and 74 by the Eastern Cooperative Oncology Group (ECOG) between June 1987 and March 1989. Patients were stratified according to number of involved nodes and type of primary surgery and randomized to receive the following: (1) tamoxifen 10 mg twice daily by mouth for 1 year; (2) cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 intravenously (IV) weekly for 1 year, fluorouracil (5-FU) 400 mg/m2 IV weekly for 1 year, vincristine .625 mg/m2 IV weekly for the first 10 weeks, and prednisone during weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2 (CMFVP); or (3) the combination of tamoxifen and CMFVP. RESULTS The median follow-up duration is 6.5 years, with a maximum of 12.8 years. Treatment arms are not significantly different with respect to either survival or DFS (log-rank, 2 df, P = .82 and .23, respectively). The 5-year survival rate is 77% for the tamoxifen arm, 78% for CMFVP, and 75% for the combination. No significant differences were observed in node or receptor level subsets. Severe or worse toxicity was experienced by 56% of patients on CMFVP and 61% on CMFVP plus tamoxifen, compared with 5% on tamoxifen alone. CONCLUSION CMFVP chemotherapy, either alone or in combination with tamoxifen, has not been shown to be superior to tamoxifen alone in the treatment of postmenopausal women with node-positive, ER-positive, operable breast cancer.

One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.

1993 ◽  
Vol 11 (9) ◽  
pp. 1710-1716 ◽  
Author(s):  
S E Rivkin ◽  
S Green ◽  
B Metch ◽  
W R Jewell ◽  
J J Costanzi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Adjuvant Treatment ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Node Positive ◽  
Disease Free

PURPOSE To determine if prolonged adjuvant treatment (2 years v 1 year) with combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil [5-FU], vincristine, and prednisone [CMFVP]) in poor-prognosis breast cancer patients (estrogen receptor [ER]-negative, stage II to IIIA) would result in improved disease-free and overall survival rates. PATIENTS AND METHODS Four hundred forty-five women with ER-negative node-positive breast cancer were enrolled by the Southwest Oncology Group (SWOG) over a period of 5 years (1979 to 1984). Randomized assignments were made to either 1 or 2 years of adjuvant CMFVP. Doses were daily oral cyclophosphamide 60 mg/m2, intravenous (i.v.) weekly methotrexate 15 mg/m2, i.v. weekly 5-FU 400 mg/m2, i.v. weekly vincristine .625 mg/m2 for the first 10 weeks, and prednisone weeks 1 through 6 with doses decreasing from 30 mg/m2 to 10 mg/m2. RESULTS The median follow-up duration is 8.6 years, with a maximum of 11.3 years. Treatment arms were not significantly different as regards either survival or disease-free survival rates (P = .33 and P = .24, respectively). The five-year survival rate is 57% on the 1-year arm and 62% on the 2-year arm. Patients with three or fewer nodes and premenopausal status were associated with improved survival. Compliance on the 2-year arm was poor, with only 37% completing the full 2 years of treatment. SWOG grade 3 to 4 toxicity was experienced by 47% of patients on the 1-year arm and by 52% on the 2-year arm. There were no treatment-related deaths. CONCLUSION We conclude that 2-year adjuvant treatment with CMFVP is not an improvement over 1-year treatment. Moreover, 2 years of CMFVP is difficult to complete. However, the results are not definitely negative. A moderate improvement attributed to prolonged chemotherapy, especially among patients with four or more positive nodes, cannot be ruled out.

Bayesian Frailty Model for Time to Event Breast Cancer Data

2011 ◽  
Vol 4 (2) ◽  
pp. 8-12
Author(s):  
Leo Alexander T Leo Alexander T ◽  
◽  
Pari Dayal L Pari Dayal L ◽  
Valarmathi S Valarmathi S ◽  
Ponnuraja C Ponnuraja C ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Frailty Model ◽  
Breast Cancer Data ◽  
Time To Event ◽  
Cancer Data

AGE FEATURES OF MOLECULAR-BIOLOGICAL SUBTYPES OF BREAST CANCER IN THE REPUBLIC OF UZBEKISTAN

2018 ◽  
Vol 64 (2) ◽  
pp. 196-199
Author(s):  
Gulya Miryusupova ◽  
G. Khakimov ◽  
N. Shayusupov
Keyword(s):  
Breast Cancer ◽  
Cancer Care ◽  
Indigenous Women ◽  
Morbidity And Mortality ◽  
Breast Cancer Data ◽  
Female Population ◽  
Cancer Data ◽  
Age Related ◽  
The Republic ◽  
Age Features

According to the results of breast cancer data in the Republic of Uzbekistan in addition to the increase in morbidity and mortality from breast cancer among women the presence of age specific features among indigenous women in the direction of “rejuvenating” of the disease with all molecular-biological (phenotypic) subtypes of breast cancer were marked. Within the framework of age-related features the prevalence of the least favorable phenotypes of breast cancer was found among indigenous women: Her2/neu hyperexpressive and three times negative subtype of breast cancer. The data obtained made it possible to build a so-called population “portrait” of breast cancer on the territory of the Republic, which in turn would contribute to further improvement of cancer care for the female population of the country.

Sign in / Sign up

Export Citation Format

Share Document